ARDX - Ardelyx Inc. - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

758.9M

Cash

130.4M

Avg Qtr Burn

-21.8M

Short % of Float

7.93%

Insider Ownership

1.51%

Institutional Own.

41.01%

Qtr Updated

03/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Ibsrela (Tenapanor) (NHE3 sodium transport inhibitor) Details Irritable bowel syndrome, Constipation	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XPHOZAH (Tenapanor) (Phosphate Absorption Inhibitor) Details Electrolyte disorder, Hyperphosphatemia, Kidney disease, Chronic kidney disease	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RDX013 Details Hyperkalemia	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.